CBSC (Cardiac Biotech Solutions) Shares Buyback Ratio %: -4.62 (As of Jul. 25, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Cardiac Biotech Solutions Shares Buyback Ratio %?

Cardiac Biotech Solutions CBSC Shares Buyback Ratio % is -4.62 as of Jul. 25, 2026.

Shares Outstanding (EOP) are shares that have been authorized, issued, and purchased by investors and are held by them.

GuruFocus calculates shares buyback ratio using previous shares outstanding minus the current shares outstanding, and then divides by previous shares outstanding. Cardiac Biotech Solutions's current shares buyback ratio was -4.62%.

Cardiac Biotech Solutions Shares Buyback Ratio % Related Terms

Cardiac Biotech Solutions Shares Buyback Ratio % Historical Data

* Premium members only.

The historical data trend for Cardiac Biotech Solutions's Shares Buyback Ratio % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cardiac Biotech Solutions Shares Buyback Ratio % Chart

Cardiac Biotech Solutions Annual Data
Trend Mar21 Mar22 Mar23 Mar24 Mar25
Shares Buyback Ratio %
0.00 0.00 -15.39 -19.11 -5.12

Cardiac Biotech Solutions Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Mar25 Jun25
Shares Buyback Ratio % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -8.99 -1.63 -1.17 -2.25 -1.14

Cardiac Biotech Solutions Shares Buyback Ratio % Calculation

Cardiac Biotech Solutions's Shares Buyback Ratio for the fiscal year that ended in Mar. 2025 is calculated as

Shares Buyback Ratio=(Shares Outstanding (EOP) (A: Mar. 2024 ) - Shares Outstanding (EOP) (A: Mar. 2025 )) / Shares Outstanding (EOP) (A: Mar. 2024 )
=(154.272 - 162.174) / 154.272
=-5.12%

Cardiac Biotech Solutions's Shares Buyback Ratio for the quarter that ended in Jun. 2025 is calculated as

Shares Buyback Ratio=(Shares Outstanding (EOP) (A: Mar. 2025 ) - Shares Outstanding (EOP) (A: Jun. 2025 )) / Shares Outstanding (EOP) (A: Mar. 2025 )
=(162.174 - 164.021) / 162.174
=-1.14%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Shares Buyback Ratio % →
What does a Shares Buyback Ratio % of -4.62 mean?
Cardiac Biotech Solutions (CBSC) has a Shares Buyback Ratio % of -4.62 as of Jul. 25, 2026. Share buyback ratio is the percent change of a company's shares outstanding from two periods. View historical data on Cardiac Biotech Solutions and its competitors.
Is Cardiac Biotech Solutions' Shares Buyback Ratio % too high?
Cardiac Biotech Solutions' current Shares Buyback Ratio % is -4.62.
How does Cardiac Biotech Solutions' Shares Buyback Ratio % compare to LUCY and NXGL?
Cardiac Biotech Solutions' Shares Buyback Ratio % of -4.62 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Shares Buyback Ratio % for a Medical Devices & Instruments company?
A good Shares Buyback Ratio % depends on the Medical Devices & Instruments industry context. However, Shares Buyback Ratio % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Shares Buyback Ratio % mean?
A high Shares Buyback Ratio % can signal that a stock is expensive relative to its fundamentals. Share buyback ratio is the percent change of a company's shares outstanding from two periods. View historical data on Cardiac Biotech Solutions and its competitors. Cardiac Biotech Solutions's current Shares Buyback Ratio % is -4.62. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cardiac Biotech Solutions stock overvalued right now?
Cardiac Biotech Solutions (CBSC) has a current Shares Buyback Ratio % of -4.62. The current Shares Buyback Ratio % is -4.62. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Shares Buyback Ratio % calculated?
Shares Buyback Ratio % is calculated from a company's financial statements. For Cardiac Biotech Solutions (CBSC), the current Shares Buyback Ratio % is -4.62 as of Jul. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Cardiac Biotech Solutions Business Description

Address 10845 Griffith Peak Drive, Suite 200, Las Vegas, NV, USA, 89135
Cardiac Biotech Solutions Inc, through its U.S. and international subsidiaries, provides products and services in the ambulatory non-invasive cardiac monitoring space. The FDA and CE cleared EKG devices, interactive cloud-based acquisition software, and smartphone apps for both iOS and Android platforms, provide improved compliance for patients at risk of abnormal heart rhythms as well as more accurate information for physicians.